# Jinju Biomedicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jinju-biomedicine

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Latest round: Series A (Nov 19, 2025)
- Investors on record: 1

## About

Founded in 2024 and based in Nanjing, China, Jinju Biomedicine operates as an innovative biotechnology company specializing in stem cell therapy platforms. The company provides stem cell injection products and regenerative medicine solutions for multiple therapeutic areas, including orthopedics, cardiovascular diseases, pulmonary hypertension, and aesthetic anti-aging treatments. In November 2025, Jinju Biomedicine raised Series A funding from new investor Tenykin Capital.
The company works with healthcare institutions and research partners to develop stem cell injection products and therapy platforms. Its offerings include minimally invasive stem cell treatments for musculoskeletal and cardiovascular conditions, as well as anti-aging and aesthetic applications.
The company’s revenue is generated by developing and commercializing stem cell therapy products and providing related clinical services.

## Funding rounds

- Series A, Nov 19, 2025 — Tenykin Capital

## Investors

- Tenykin Capital (https://capitalatlas.ai/funds/tenykin-capital) — Series A